Denali Therapeutics Profile

Performance

   

Odds of Distress

Check how we calculate scores
Equity ratings for Denali Therapeutics are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting June 17, 2019 and ending today September 15, 2019. Click here to learn more.
18.59
USD 0.23  1.22%

Denali Therapeutics Summary

Denali Therapeutics (DNLI) is traded on BATS Exchange in USA. It is located in 161 Oyster Point Boulevard and employs 230 people. Denali Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 1.86B. Denali Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 95.84M outstanding shares of which 11M shares are currently shorted by private and institutional investors with about 36.04 trading days to cover. The company currently holds about 478.6M in cash with (15.13M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.99.
Check Denali Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Denali Therapeutics Target Price Odds Analysis

Odds Below 18.59HorizonTargetOdds Above 18.59
52.06%30 days 18.59 47.85%
Based on normal probability distribution, the odds of Denali Therapeutics to move above current price in 30 days from now is about 47.85% (This Denali Therapeutics probability density function shows the probability of Denali Therapeutics Stock to fall within a particular range of prices over 30 days) .

Denali Therapeutics Top Holders

Denali Therapeutics Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Denali Therapeutics Key Fundamentals

Denali Therapeutics Against Markets

Denali Therapeutics Vital Trading Data

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. Denali Therapeutics Inc. was incorporated in 2013 and is based in South San Francisco, California. Denali Therapeutics operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 230 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Denali Therapeutics SEC Filings
Denali Therapeutics SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameDenali Therapeutics
CEORyan WattsView All
Thematic Classification
Currently Active Investing Idea
  Pharmaceutical Products
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
LocationCalifornia U.S.A
Business Address161 Oyster Point Boulevard
ExchangeBATS Exchange
CUSIP24823R105
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.denalitherapeutics.com
Phone650 866 8548
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterJune 30, 2019
Last Fiscal Year EndDecember 31, 2018
Date Short InterestAugust 15, 2019

Denali Therapeutics Corporate Directors

David Schenkein Independent Director
Peter Klein Independent Director
Douglas Cole Independent Director
Additionally see Investing Opportunities. Please also try Transaction History module to view history of all your transactions and understand their impact on performance.
Search macroaxis.com